Strata Oncology Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
138
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$90M
- Investors
-
12
Strata Oncology General Information
Description
Operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer. The company partners with major healthcare systems across the country, who systematically send their cancer patient's biopsies to high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials, enabling healthcare providers to provide actionable insight to the lives of cancer patients.
Contact Information
Website
www.strataoncology.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Laboratory Services (Healthcare)
Biotechnology
Primary Office
- 8192 Jackson Road
- Suite A
- Ann Arbor, MI 48103
- United States
+1 (734) 000-0000
Strata Oncology Timeline
Strata Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 28-Jul-2021 | $90M | 00000 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC | 04-Nov-2020 | 000 | 0000 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series B) | 23-May-2018 | $26M | $38M | 0000 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 02-Jun-2016 | $12M | $12M | 0000 | Completed | Startup |
Strata Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series C-1 | 000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 0.000 |
| Series B | 2,625,918 | $0.000010 | 8% | $9.9 | $9.9 | 1x | $9.9 | 23.29% |
| Series A | 3,054,529 | $0.000010 | 8% | $4.04 | $4.04 | 1x | $4.04 | 27.09% |
Strata Oncology Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer. The co
Decision/Risk Analysis
Ann Arbor, MI
138
As of 2022
00000
0000
0000-00-00
00000000000
00000
000000
tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000000000000
Wuxi, China
00000
00000000
00000
000 (0
derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000000
Auburndale, MA
00
As of 0000
000.00
00000000000
000.00
Add Comparison
Strata Oncology Competitors (21)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GeneCast Biotechnology | Private Equity-Backed | Wuxi, China | 00000 | 00000000 | 00000 | |
| 000 (0000000000000 | Venture Capital-Backed | Auburndale, MA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000000 000000000 | Formerly VC-backed | Seattle, WA | 000 | 00000 | 00000000 | 00000 |
| 000000 | Venture Capital-Backed | Boston, MA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 | Venture Capital-Backed | Houston, TX | 00 | 00000 | 0000000000 0 | 00000 |
Strata Oncology Patents
Strata Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3899537-A4 | Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer | Pending | 19-Dec-2018 | 00000000000 | 0 |
| AU-2019403339-A1 | Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer | Pending | 19-Dec-2018 | 0000000000 | |
| CA-3124471-A1 | Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer | Pending | 19-Dec-2018 | 0000000000 | |
| EP-3899537-A1 | Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer | Pending | 19-Dec-2018 | 0000000000 | |
| US-20220081724-A1 | Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer | Pending | 19-Dec-2018 | C12Q1/6886 |
Strata Oncology Executive Team (11)
Strata Oncology Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amy Kobe | Baird Capital | Board Member | 000 0000 |
| Christopher O'Donnell Ph.D | Pfizer Ventures | Board Member | 000 0000 |
| Dan Kidle | Arboretum Ventures | Board Observer | 000 0000 |
| Daniel Rhodes Ph.D | Strata Oncology | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
| Jan Garfinkle | Arboretum Ventures | Board Member | 000 0000 |
Strata Oncology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Strata Oncology Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Cormorant Asset Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Highside Capital Management | Family Office | Minority | 000 0000 | 000000 0 | |
| Monashee Investment Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Wellington Management | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 |